Last reviewed · How we verify
NCT05973097
Treatment of Oral Lichen Planus With Paeoniflorin and Photodynamic Therapy
NA trial testing total glucosides of paeony treatment in Oral Lichen Planus in 156 participants. Currently enrolling.
30 December 2028
Quick facts
| Lead sponsor | Peking University Third Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 156 |
| Start date | 30 July 2023 |
| Primary completion | 30 December 2028 |
| Estimated completion | 30 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- total glucosides of paeony treatment — full drug profile →
- photodynamic therapy treatment
- glucosides of paeony and photodynamic therapy combined treatment
Conditions studied
- Oral Lichen Planus — all drugs for Oral Lichen Planus →
Sponsor
Peking University Third Hospital
Who can join
18 and older, any sex, with Oral Lichen Planus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Oral lichen planus (OLP) is a common chronic inflammatory disease of the oral mucosa and is considered a precancerous condition. It is characterized by white reticular changes in the oral mucosa, which can progress to erosions and cause pain in severe cases. The pathogenesis of OLP is still unclear, but it is believed to be a T-lymphocyte-mediated autoimmune disease. Currently, only symptomatic treatments are available, and there is no definitive cure. In this project, we plan to use TCM differentiation to categorize OLP patients and conduct a randomized controlled clinical trial to demonstrate the enhanced therapeutic effect of paeoniflorin combined with photodynamic therapy for OLP. The implementation of this project will provide new insights into the clinical management of OLP, improve our understanding of the treatment mechanisms, and have important theoretical and clinical implications.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05973097
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Oral Lichen Planus
Currently open trials in the same condition.
- NCT06981767 — Effect of Topical Bromelain Versus Topical Corticosteroids in the Management of Oral Lichen Planus · Phase 2 · recruiting
- NCT07131813 — Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus · Phase 4 · recruiting
- NCT06932848 — The Therapeutic Effect of Curcumin in Nanogels Compared to 0.1% FAO in the Management of Oral Lichen Planus · NA · recruiting
- NCT07100613 — Mucoadhesive Modified-Release Formulations for the Topical Treatment of Symptomatic Oral Lichen Planus · Phase 2 · recruiting
- NCT06233591 — Evaluating LP-10 in Subjects With OLP · Phase 2 · active not recruiting
Other Peking University Third Hospital trials
Trials by the same sponsor.
- NCT07532421 — Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life · NA · not yet recruiting
- NCT07470255 — Detection of Diabetic Foot Skin Damage Using Plantar Mechanical Parameters · not yet recruiting
- NCT07453381 — Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA/INOCA Patients: A Prospective · not yet recruiting
- NCT07452354 — AI-Based Diabetic Foot Recurrence Cohort · not yet recruiting
- NCT07423819 — Sports Rehabilitation Therapy for Knee Joint Sports Injuries: A Case Study of Anterior Cruciate Ligament Injury and Pate · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05973097 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University Third Hospital
- Last refreshed: 2 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05973097.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing